Vol 10, No 1 (2025)
Original article
Published online: 2025-03-03
Prognostic and clinicopathological significance of CD44, MMP-2, and MMP-9 expression in clear cell renal cell carcinoma
1
, 1, 1, 1
, 1, 1, 1
Med Res J 2025;10(1):8-18.
Abstract
Introduction: CD44 is a well-known marker for cancer stem cells. Matrix metalloproteinases MMP-2 and MMP-9 are essential for tumor growth, invasion, and metastasis. This study aimed to analyze clinicopathologic and prognostic values of CD44, MMP-2, and MMP-9 expression in clear cell renal cell carcinoma (ccRCC) patients.
Material and methods: A total of 243 patients with a diagnosis of ccRCC were included in the study. All tumors were examined for CD44, MMP-2, and MMP-9 expression by immunohistochemistry. Membranous and cytoplasmic expression levels were scored by semiquantitative methods, and the correlation between clinicopathological parameters and patient outcome was investigated.
Results: A positive correlation was attained between CD44 and MMP-2 and between CD44 and MMP-9 expression levels. CD44 was positively correlated with: grade, pathologic stage, tumor size, percentage of tumor necrosis and sarcomatoid transformation, presence of angioinvasion, and renal sinus fat invasion. Univariate analysis showed that patients with increased (moderate and high) CD44 expression had remarkably shorter overall survival than patients with lower CD44 expression. In turn, MMP-9 and MMP-2 were not positively correlated either with the clinicopathological parameters or with patients’ survival.
Conclusions: CD44 mainly contributes to the aggressiveness of ccRCC and determines the decisive role of cancer stem cells in the mechanisms of ccRCC carcinogenesis. CD44 seems to be an independent factor of poor outcome, and therefore the authors consider it a valuable prognostic marker in patients with ccRCC. However, MMP-2 and MMP-9 might play roles during extracellular matrix invasion in certain aspects of ccRCC progression but do not affect long-term adverse events.
Keywords: CD-44clear cell renal cell carcinomaimmunohistochemistryMMP-2MMP-9renal cell carcinoma
References
- Costa WH, Rocha RM, Cunha IW, et al. Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance. Int Braz J Urol. 2012; 38(4): 456–465.
- Gayyed M, Soliman M, El-Hussieny M. Clinical utility of MCM2 and CD44 expression in clear cell renal cell carcinoma. Polish Journal of Pathology. 2020; 71(4): 339–346.
- Li X, Ma X, Chen L, et al. Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2015; 5: 13157.
- Ma C, Komohara Y, Ohnishi K, et al. Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Sci. 2016; 107(5): 700–707.
- Kim SP, Alt AL, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol. 2011; 185(6): 2035–2039.
- Jeong BJ, Liang ZL, Huang SM, et al. CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy. Exp Ther Med. 2012; 3(5): 811–817.
- Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008; 65(3): 235–262.
- Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma. World J Urol. 2010; 28(3): 319–327.
- Zanjani LS, Madjd Z, Abolhasani M, et al. Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma. Biomark Med. 2018; 12(1): 45–61.
- Yoshida GoJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci. 2016; 107(1): 5–11.
- Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013; 32(44): 5191–5198.
- Bomken S, Fiser K, Heidenreich O, et al. Understanding the cancer stem cell. Br J Cancer. 2010; 103(4): 439–445.
- Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012; 12(2): 133–143.
- Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012; 2012: 708036.
- Di Carlo A. Matrix metalloproteinase-2 and -9 in the sera and in the urine of human oncocytoma and renal cell carcinoma. Oncol Rep. 2012; 28(3): 1051–1056.
- DI Carlo A. Matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in sera and urine of patients with renal carcinoma. Oncol Lett. 2014; 7(3): 621–626.
- Lu H, Yang Z, Zhang H, et al. The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Exp Ther Med. 2013; 5(3): 890–896.
- Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3): 161–174.
- Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755(1): 37–69.
- Delahunt B, Cheville JC, Martignoni G, et al. Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37(10): 1490–1504.
- Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022; 82(5): 458–468.
- Amin MB, Edge S, Greene F, et al. et al.. AJCC cancer staging manual. 8th edition. New York: Springer Verlag. ; 2016.
- Chrabańska M, Rynkiewicz M, Kiczmer P, et al. Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study. J Clin Med. 2022; 11(17).
- Lee YM, Kim JM, Lee HJ, et al. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas. Urol Oncol. 2019; 37(10): 742–748.
- Chand P, Garg A, Singla V, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11(2): 155–168.
- Eun HS, Cho SY, Lee BS, et al. Cytochrome P450 4A11 expression in tumor cells: A favorable prognostic factor for hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2019; 34(1): 224–233.
- Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019; 13(Suppl 1): S31–S34.
- DEVRİM T, BALCI M. COEXISTENCE OF CD44 AND KI-67 AS THE PROGNOSTIC MARKERS IN RENAL CELL CARCINOMA. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi. 2020; 22(1): 79–88.
- Zhang F, Xie Y, Ma X, et al. Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma. Urol Oncol. 2019; 37(3): 184.e9–184.e17.
- Bussolati B, Dekel B, Azzarone B, et al. Human renal cancer stem cells. Cancer Lett. 2013; 338(1): 141–146.
- Rioux-Leclercq N, Epstein JI, Bansard JY, et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol. 2001; 32(11): 1209–1215.
- Uchino M, Kojima H, Wada K, et al. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer. 2010; 10: 414.
- Qin J, Yang B, Xu BQ, et al. Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. Int J Clin Exp Pathol. 2014; 7: 3235–3244.
- Lim SoD, Young AN, Paner GP, et al. Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch. 2008; 452(1): 49–55.
- Lucin K, Matusan K. Dordevi ́c G, Stipi ́c D. Prognostic significance of CD44 molecule in renal-cell carcinoma. Croat Med J. 2004; 45: 703–708.
- Tawfik OW, Kramer B, Shideler B, et al. Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med. 2007; 131(2): 261–267.
- Bamias A, Chorti M, Deliveliotis C, et al. Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology. 2003; 62(2): 368–373.
- McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000; 6(4): 149–156.
- Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012; 1825(1): 29–36.
- Bianco BC, Scotti FM, Vieira DSC, et al. Immunohistochemical expression of matrix metalloproteinase-1, matrix metalloproteinase-2 and matrix metalloproteinase-9, myofibroblasts and Ki-67 in actinic cheilitis and lip squamous cell carcinoma. Int J Exp Pathol. 2015; 96(5): 311–318.
- Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 2009; 21(5): 1323–1333.
- Kallakury BV, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001; 7(10): 3113–3119.
- Struckmann K, Mertz Kd, Steu S, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol. 2008; 214(4): 464–471.
- Sumi T, Nakatani T, Yoshida H, et al. Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma. Oncol Rep. 2003; 10: 567–570.
- Qiao Zk, Li Yl, Lu Ht, et al. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J Surg Oncol. 2013; 11: 1.
- Cho NH, Shim HS, Rha SY, et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol. 2003; 44(5): 560–566.
- Kugler A, Hemmerlein B, Thelen P, et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol. 1998; 160(5): 1914–1918.
- Kamiya N, Kishimoto T, Suzuki H, et al. Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer. 2003; 106(4): 480–485.
- Lein M, Jung K, Laube C, et al. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer. 2000; 85(6): 801–804, doi: 10.1002/(sici)1097-0215(20000315)85:6<801::aid-ijc11>3.0.co;2-c.